Trial Profile
A Phase II, Multicenter, Single-Arm, Open-Label Clinical Trial to Evaluate the Safety and Efficacy of Triple Therapy With Dolutegravir Plus 2 NRTIs, in Treatment-Naïve HIV-2 Infected Subjects
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 05 Nov 2021
Price :
$35
*
At a glance
- Drugs Abacavir/dolutegravir/lamivudine (Primary) ; Dolutegravir (Primary) ; Emtricitabine (Primary) ; Emtricitabine/tenofovir disoproxil fumarate (Primary) ; Tenofovir disoproxil fumarate (Primary)
- Indications HIV-2 infections
- Focus Therapeutic Use
- Sponsors Blueclinical
- 29 Aug 2019 Status changed from recruiting to completed.
- 23 Mar 2017 New trial record